Status: Recruiting
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
Participants needed: 1,116
Trial details
Phase: Phase 2Age: 1-55Biological sex: AllType: InterventionalSponsor: Victoria Biomedical Research InstituteUpdated: Jun 29, 2026Locations: 1
Eligibility criteria
Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with... [+9]
Prospective study participant, LAR and/or impartial witness (where applicable) d... [+34]